Oxaliplatin-related neurotoxicity: How and why?

Cersosimo, 2005, Oxaliplatin-associated neuropathy: a review, Ann Pharmacother, 39, 128, 10.1345/aph.1E319

Extra, 1998, Pharmacokinetics and safety profile of oxaliplatin, Semin Oncol, 25, 13

Holmes, 1998, Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model, Toxicol Sci, 46, 342

Grolleau, 2001, A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels, J Neurophysiol, 85, 2293, 10.1152/jn.2001.85.5.2293

Zhang, 1998, Glutathione-related mechanisms in cellular resistance to anticancer drugs, Int J Oncol, 12, 871

Ban, 1996, Transfection of glutathione S-transferase (GST)-pi antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan, and etoposide, Cancer Res, 56, 3577

Cascinu, 2002, Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomised, double-blind, placebo-controlled trial, J Clin Oncol, 20, 3478, 10.1200/JCO.2002.07.061

Adelsberger, 2000, The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons, Eur J Pharmacol, 406, 25, 10.1016/S0014-2999(00)00667-1

Gamelin, 2002, Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures, Semin Oncol, 29, 21, 10.1053/sonc.2002.35525

Lehky, 2004, Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy, Muscle Nerve, 29, 387, 10.1002/mus.10559

Krishnan, 2005, Oxaliplatin-induced neurotoxicity and the development of neuropathy, Muscle Nerve, 32, 51, 10.1002/mus.20340

Nakayama, 2002, Failure to find evidence for association between voltage-gated sodium channel gene SCN2A variants and febrile seizures in humans, Neurosci Lett, 329, 249, 10.1016/S0304-3940(02)00651-1

Cavaletti, 2002, Circulating nerve growth factor level changes during oxaliplatin treatment-induced neurotoxicity in the rat, Anticancer Res, 22, 4199

Screnci, 2000, Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs, Br J Cancer, 82, 966, 10.1054/bjoc.1999.1026

Gent, 2001, An overview of chemotherapy-induced peripheral sensory neuropathy, focusing on oxaliplatin, Int J Palliat Nurs, 7, 354, 10.12968/ijpn.2001.7.7.9020

Berretta, 2004, Dysphonia as an unusual toxic event of oxaliplatin-based chemotherapy, J Chemother, 16, 595, 10.1179/joc.2004.16.6.595

Extra, 1998, Pharmacokinetics and safety profile of oxaliplatin, Semin Oncol, 25, 13

Wilson, 2002, Acute oxaliplatin-induced peripheral nerve hyperexcitability, J Clin Oncol, 20, 1767, 10.1200/JCO.2002.07.056

Kemeny, 2004, Randomised multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer, J Clin Oncol, 22, 4701, 10.1200/JCO.2004.03.119

Rothenberg, 2003, Therapeutic strategies for metastatic colorectal cancer: simultaneous, sequential, or specific?, J Clin Oncol, 21, 3716, 10.1200/JCO.2003.07.941

Rothenberg, 2003, Superiority of oxaliplatin and fluorouracil–leucovorin compared with either therapy alone in patients with progressive colorectal cancer after CPT11 and fluorouracil–leucovorin: interim results of a phase III trial, J Clin Oncol, 21, 2059, 10.1200/JCO.2003.11.126

Maindrault-Goebel, 1999, Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR, Eur J Cancer, 35, 1338, 10.1016/S0959-8049(99)00149-5

Maindrault-Goebel, 2001, High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7), Eur J Cancer, 37, 1000, 10.1016/S0959-8049(01)00068-5

Tournigand, 2004, FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomised GERCOR study, J Clin Oncol, 22, 229, 10.1200/JCO.2004.05.113

Giantonio, 2005, High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200, Proc Am Soc Clin Oncol, 23, 169

de Gramont, 2000, Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer, J Clin Oncol, 18, 2938, 10.1200/JCO.2000.18.16.2938

Goldberg, 2004, A randomised controlled trial of fluorouracil plus leucovorin, CPT11, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer, J Clin Oncol, 22, 23, 10.1200/JCO.2004.09.046

Cassidy, 2004, XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer, J Clin Oncol, 22, 2084, 10.1200/JCO.2004.11.069

Fernando, 2005, A phase II study of oxaliplatin, capecitabine and bevacizumab in the treatment of metastatic colorectal cancer, Proc Am Soc Clin Oncol, 23, 3556, 10.1200/jco.2005.23.16_suppl.3556

Andre, 2004, Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer, N Engl J Med, 350, 2343, 10.1056/NEJMoa032709

de Gramont, 2005, Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a median follow-up of 4 years, Proc Am Soc Clin Oncol, 23, 3501, 10.1200/jco.2005.23.16_suppl.3501

Wolmark, 2005, A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: results of NSABP Protocol C-07, Proc Am Soc Clin Oncol, 23, 3500, 10.1200/jco.2005.23.16_suppl.lba3500

Schmoll, 2005, Capecitabine plus oxaliplatin (XELOX) versus bolus FULV as adjuvant therapy for patients with stage III colon cancer: preliminary safety findings from a randomised phase III trial, The World Congress of Gastrointestinal Cancer, O-028

Lersch, 2002, Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer, Clin Colorectal Cancer, 2, 54, 10.3816/CCC.2002.n.011

Mariani, 2000, Oxaliplatin induced neuropathy: could gabapentin be the answer?, Proc Am Soc Clin Oncol, 19, 609

Eckel, 2002, Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study, Dtsch Med Wochenschr, 127, 78, 10.1055/s-2002-19594

Wong, 2005, A phase III double blinded, placebo controlled. Randomized trial of gabapentin in patients with chemotherapy-induced peripheral neuropathy: a North Central Cancer Treatment Group Study, Proc Am Soc Clin Oncol, 23

Penz, 2001, Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy, Ann Oncol, 12, 421, 10.1023/A:1011184609963

Samuels, 2003, Ongoing prospective multicenter safety study of the cytoprotectant amifostine given subcutaneously: overview of trial design, Semin Oncol, 30, 94, 10.1053/j.seminoncol.2003.11.018

Cascinu, 2002, Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomised, double-blind, placebo-controlled trial, J Clin Oncol, 20, 3478, 10.1200/JCO.2002.07.061

Mattioli, 2005, High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer, Ann Oncol, 16, 1147, 10.1093/annonc/mdi222

Grothey, 2005, Clinical management of oxaliplatin-associated neurotoxicity, Clin Colorectal Cancer, 5, S38, 10.3816/CCC.2005.s.006

Grothey, 2003, Oxaliplatin-safety profile: neurotoxicity, Semin Oncol, 30, 5, 10.1016/S0093-7754(03)00399-3

Gedlicka, 2002, Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid, J Clin Oncol, 20, 3359, 10.1200/JCO.2002.99.502

Gamelin, 2004, Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer, Clin Cancer Res, 10, 4055, 10.1158/1078-0432.CCR-03-0666

Park, 2001, Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer, Cancer Res, 61, 8654

Park, 2004, Genomic profiling as predictor of toxicity in patients with advanced colorectal cancer treated with platinum-based chemotherapy, Proc Am Soc Clin Oncol, 22, 3627, 10.1200/jco.2004.22.14_suppl.3627

Cavaletti, 2001, Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat, Eur J Cancer, 37, 2457, 10.1016/S0959-8049(01)00300-8

Gornet, 2002, Exacerbation of oxaliplatin neurosensory toxicity following surgery, Ann Oncol, 13, 1315, 10.1093/annonc/mdf254

Holmes, 1998, Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model, Toxicol Sci, 46, 342

Raymond, 1998, Oxaliplatin: a review of preclinical and clinical studies, Ann Oncol, 9, 1053, 10.1023/A:1008213732429

Figg, 1997, Pharmacokinetics of elemental platinum (ultrafiltrate and total) after a thirty minute intravenous infusion of ormaplatin, Biopharm Drug Disp, 18, 347, 10.1002/(SICI)1099-081X(199705)18:4<347::AID-BDD23>3.0.CO;2-O

Aamdal, 1997, Zeniplatin in advanced malignant melanoma and renal cancer: phase II studies with unexpected nephrotoxicity, Cancer Chemother Pharmacol, 40, 439, 10.1007/s002800050683

Kudelka, 1997, A phase II and pharmacokinetic study of enloplatin in patients with platinum refractory advanced ovarian carcinoma, Anticancer Drugs, 8, 649, 10.1097/00001813-199708000-00001

Theriault, 1996, A phase II study of CI-973 [SP-4-3(R)]-1,1-cyclobutane-dicarboxylato (2-)] (2-methyl-1,4-butanediamine-N,N′) platinum in patients with refractory advanced breast cancer, Cancer Chemother Pharmacol, 38, 289, 10.1007/s002800050484